Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

17 results about "Ectopic expression" patented technology

Ectopic is a word used with a prefix, ecto, meaning “out of place.” Ectopic expression is an abnormal gene expression in a cell type, tissue type, or developmental stage in which the gene is not usually expressed. The term ectopic expression is predominately used in studies using metazoans, especially in Drosophila melanogaster for research purposes.

Application of wheat TabHLH93 protein or coding gene thereof in regulation and control of plant grain development

The invention belongs to the technical field of plant genetic engineering molecular breeding, and particularly relates to application of wheat TabHLH93 protein or a coding gene thereof in regulation and control of plant grain development. According to the invention, a binary expression vector capable of realizing ectopic expression of the TabHLH93 gene is constructed and is genetically transformed into common wheat to obtain a progeny with high expression of the TabHLH93 gene, so that overexpression of the TabHLH93 gene is realized, and it is verified that the TabHLH93 has a function of regulating and controlling the size of wheat grains and also has an important regulation and control effect on agronomic characters such as wheat plant height, tiller number, spike length and thousand seed weight. A candidate gene with an important application prospect is provided for wheat high-yield genetic improvement, and the gene has important significance for guaranteeing grain safety.
Owner:SHANDONG UNIV

Application of Foxn3 gene or protein in preparation of medicine for treating retina ciliary lesion

PendingCN120241964ASenses disorderNervous disorderMouse RetinaKnockout animal
The invention discloses application of a Foxn3 gene or protein in preparation of a medicine for treating retina ciliary lesion. Experimental results show that Foxn3 is crucial to inhibition of cilia gene expression in non-photosensitive neurons such as bipolar cells and non-long-process cells, neuron functions in retinas of Foxn3 knockout mice are damaged, and deletion of Foxn3 causes ectopic cilia gene expression and abnormal cilia of the non-photosensitive neurons. The invention discloses a promoter directly combined with Foxn3 and inhibiting cilia genes and cilia transcription factors. The promoter comprises Foxj1 and Rfx family members. Foxn3 is used as a key transcription inhibition factor, and a proper cilia structure of the retinal neuron is ensured by preventing non-photosensitive neurons from adopting photosensitive cell-like cilia characteristics. The invention provides a therapeutic target and a drug for retina ciliary lesion.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Gene for inducing apomixis of plants, induction method formed by gene and application of gene

ActiveCN120330218APlant peptidesFermentationBiotechnologyApomixis
The invention discloses a gene for inducing apomixis of plants, an inducing method formed by the gene and application of the gene. Relates to the field of biotechnology and plant breeding. The genes for inducing the apomixis of the plants are respectively arabidopsis thaliana AtCPRO1, corn Zm CPRO3, corn Zm CPRO4, soybean GlCPRO2 and rape Bna CPRO8. According to the induction method of the gene composition, AtCPRO1 in arabidopsis thaliana, Zm CPRO3 and Zm CPRO4 in corn, GlCPRO2 in soybean and Bna CPRO8 in oilseed rape which exist in the nature are introduced into rice respectively, ectopic expression is performed in egg cells, then combination with a MiMe system is performed, on the premise that growth and development of plants are not affected, generation of cloned diploid progeny can be induced, and the yield of the cloned diploid progeny is increased. The invention provides a new solution for rice breeding, and has important application prospect and economic value.
Owner:SANYA NATIONAL INSTITUTE OF SOUTHERN BREEDING CHINESE ACADEMY OF AGRICULTURAL SCIENCES +1

Streptomyces-sourced siderophore-polyketone hybrid product synthesis related gene cluster, genetically engineered bacterium and application of genetically engineered bacterium

The invention belongs to the technical field of genetic engineering and biosynthesis, and particularly relates to a streptomyces-sourced siderophore-polyketone hybrid product synthesis related gene cluster, a genetically engineered bacterium and application of the genetically engineered bacterium. The invention provides an NIS siderophore synthetase gene cluster. The gene cluster is selected from a gene cluster BGC19 or a gene cluster desB. Meanwhile, the invention discloses two biological heterologous or ectopic expression engineering bacteria for producing the hybrid siderophore and application of the siderophore-polyketone hybrid compound by taking streptomyces as a host, and discloses structures and activities of the siderophore-polyketone hybrid compound produced by the two engineering bacteria. The invention provides a scheme for the construction of engineering bacteria for generating new hybrid compounds by utilizing the expression of non-adjacent gene clusters at specific sites and functional combination among the gene clusters, also provides a new element for the biosynthesis of a novel siderophore and polyketone combination, and has good practical application value.
Owner:SHANDONG UNIV

A method for improving regeneration and genetic transformation efficiency of peanut plants by ectopic expression of AhLEC1a gene

The application belongs to the technical field of plant genetic engineering and genetic breeding, and particularly relates to a method for improving regeneration and genetic transformation efficiency of peanut plants by ectopic expression of a gene AhLEC1a The application discloses a method for improving regeneration efficiency and genetic transformation success rate of peanut plants by ectopic expression of a gene AhLEC1a The method is characterized in that a beta-estradiol inducible expression vector is constructed AhLEC1a The transgenic plants are obtained by using somatic embryo regeneration or a direct organ regeneration approach. AhLEC1a The ectopic expression of the gene can significantly improve somatic embryo induction rate (up to 100%) and the number of cells of a single explant (2.13 times of that of a control group); the explant bud induction efficiency of the direct organ regeneration approach is improved by 22% compared with that of the control group; and the transgenic positive rates of the two methods are improved by 27.81% and 6.15% respectively compared with those of the control group. The application breaks through the difficulties of low regeneration efficiency and low transformation success rate in peanut genetic transformation, and provides important technical support for peanut gene function research and molecular breeding.
Owner:CROP RES INST GUANGDONG ACAD OF AGRI SCI

New method for obtaining innate lymphoid precursors cells

PCT designated stageWO2026033019A1Blood/immune system cellsNon-embryonic pluripotent stem cellsEctopic expressionSomatic cell
Helper innate lymphoid cells (ILC) play important functions in immunity and tissue homeostasis, but their development remains poorly understood. In this study, the inventors investigated the precise function of the transcription factor NFIL3, which they established as the earliest requirement during ILC development in mouse bone marrow. Using NFIL3 retroviral ectopic expression in all-lymphoid progenitors, they showed that NFIL3 triggers a developmental process that recapitulates in vitro natural ILC development, in the absence of any other instructive signal. The present invention relates to an in vitro method for obtaining innate lymphoid precursors cells, said method comprising the step of i) culturing hematopoietic precursors cells in an appropriate culture medium, and ii) manipulating the said hematopoietic precursors cells to increase the expression or function of the Nuclear Factor Interleukin (3) Regulated (NFIL3).
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Application of wheat tabhlh93 protein or its coding gene in regulating grain development of plants

This invention belongs to the field of plant genetic engineering and molecular breeding technology, specifically relating to the application of wheat TabHLH93 protein or its encoding gene in regulating plant grain development. This invention constructs a structure capable of ectopic expression... TabHLH93 A binary expression vector for the gene was genetically transformed into common wheat. TabHLH93 Offspring with high gene expression achieved TabHLH93 The gene was overexpressed and verified, demonstrating that TabHLH93 regulates wheat grain size and plays a significant role in regulating agronomic traits such as plant height, tiller number, spike length, and thousand-grain weight. This provides a promising candidate gene for high-yield genetic improvement of wheat, which is of great importance for ensuring food security.
Owner:SHANDONG UNIV

Methods and compositions for selective generation of dopaminergic precursors

ActiveUS12534740B2Genetically modified cellsNervous system cellsSOX2Dopaminergic
The present invention provides methods of transdifferentiating a somatic cell, e.g., a fibroblast, to an induced dopaminergic precursor cell (iDP) in vitro. The methods include ectopically expressing genes of (1) one or both of Brn2 and Brn4, or a variant thereof, (2) Sox2, or a variant thereof, and (3) one or both of Foxa2 and Lmx1a, or a variant thereof, in the somatic cell, and methods for treating a neurodegenerative disease, such as Parkinson's disease, with the iDP.
Owner:TONGJI UNIV +1

Functional expression of ectopic TMC1 and TMC2 in heterologous cells

PendingUS20250145676A1Compound screeningApoptosis detectionEctopic expressionTransmembrane protein
The subject invention pertains methods for the ectopic expression of a transmembrane protein lacking plasma membrane expression in a heterologous cell line. In embodiments, transmembrane proteins Fyn-TMC1 and / or Fyn-TMC2 are fused to a membrane-anchoring motif, a Fyn lipidation tag, which provides a signal for myristoylation and palmitoylation, allowing further research on these proteins, including but not limited to their function, structure, and drug screening.
Owner:THE HONG KONG UNIV OF SCI & TECH

Cell for ectopic expression of FOXP3

PendingCN122055438AVectorsGenetically modified cellsFoxp3 expressionEctopic expression
Expression cassettes comprising FOXP3 proteins, chimeric receptors, and / or cell surface receptors are provided. Also provided herein are Treg cells comprising the expression cassettes and methods of use.
Owner:SONOMA BIOTHERAPEUTICS INC

Modified crop plant having increased expression of one or more one transcription factors specific for the plant's ESR or betl

PCT designated stageWO2026008891A1HydrolasesPlant peptidesBiotechnologyEctopic expression
The present invention relates to a modified crop plant or part thereof which exhibits increased or ectopic expression of one or more one transcription factors, which one or more transcription factors are specifically expressed in the plant's ESR and / or in the plant's BETL, or modulate gene expression of one or more ESR and / or BETL-specific genes.
Owner:KWS SAAT SE & CO KGAA +1

Method for enhancing colon cancer resisting function of Vdelta1gamma deltaT cells

PendingCN120267818AOrganic active ingredientsDigestive systemEctopic expressionOncology
The invention relates to the technical field of biological medicines, and provides a method for enhancing the colon cancer resisting function of a V delta 1 gamma delta T cell, and a CDK1 activator and the T cell are combined to prepare a colon cancer resisting medicine. According to the technical scheme, a molecular mechanism for regulating and controlling tumor antigen ectopic expression through the CDK1-NCL axis is illustrated, and the key theory blank of recognizing tumor cells through the V delta 1 gamma delta T cells is filled up; a CDK1 activator TC11 is developed to serve as an auxiliary means for enhancing the functions of the V delta 1 gamma delta T cells, and the limitation that traditional immunotherapy depends on exogenous antigen modification is broken through; in-vivo and in-vitro experiments prove that targeting CDK1 can remodel a tumor immune microenvironment, and a convertible clinical application scheme is provided for combined immunotherapy of colon cancer and other solid tumors.
Owner:HENAN CANCER HOSPITAL

Composition for regenerating retinal ganglion cells by using endogenous microglial cells and application of composition

The invention discloses a composition for regenerating retinal ganglion cells by using endogenous microglial cells and application. In-vivo microglial cell fate lineage tracking finds that a plurality of genes (Brn3b, Sox2, Cbln1 and NP1, called BSCN for short) are expressed in an ectopic manner in microglial cells, so that the microglial cells can be promoted to be converted into retinal ganglion cells. And the regenerated nodule cells project axons to the distant brain, reconstruct an optic nerve circuit and recover the impaired vision of the adult glaucoma mouse. Besides, the regenerated ganglion cells can stably survive as long as one year, and the same regeneration strategy is adopted in old-age glaucoma mice, so that the effectiveness of reprogramming regeneration of the RGCs by the BSCN is proved. Therefore, it is determined that the microglial cells are novel reprogramming seed cells, it is found that the four key genes participate in RGCs regeneration to recover vision, and new therapeutic drugs and means are provided for treatment of glaucoma and related diseases.
Owner:SHANGHAI CITY PUDONG NEW DISTRICT ZHOUPU HOSPITAL

Molecular engineering to enhance chimeric antigen receptor-mediated tumor immunotherapy

The present disclosure provides a chimeric antigen receptor (CAR) immunotherapy for treating a hematologic cancer comprising (a) genetically modifying a population of immune effector cells comprising T cell receptors (TCRs) to stably express at least one CAR, wherein the ectodomain of the CAR specifically binds a cancer antigen; (b) expanding the population of CAR-containing immune effector cells in the presence of one or more cytokines in vitro to achieve a therapeutic dose, wherein the population of CAR-containing immune effector cells exhibits a nonexhausted memory T cell phenotype; and (c) infusing eligible subjects with the CAR-containing immune effector memory T cell phenotype population of cells as needed until the hematologic cancer in the body is destroyed. The intracellular signal transduction domain of the CAR includes 4-1BB, a CD3zeta T cell activation chain and a genetically engineered 'TLE3, which can be ectopically expressed.
Owner:HACKENSACK MERIDIAN HEALTH INC

Novel method for realizing apomixis of plants

The invention provides a novel method for realizing apomixis of plants. By removing egg cell expression inhibition factors of endogenous parthenogenesis genes (including BBM1, BBM4, CPRO1, CPRO2, WUS and the like) of rice and combining with a MiMe strategy, a novel apomixis method which only depends on gene editing is realized. According to the method, a gene editing means is adopted completely, an egg cell ectopic expression technology is not involved, apomixis is achieved by removing an egg cell expression inhibition factor of a rice endogenous parthenogenesis gene, the purpose of not involved transgenosis is achieved, and production and application of an artificial apomixis technology in crops are achieved.
Owner:CHINA NAT RICE RES INST

Drug-inducible gene expression system

PCT designated stageWO2026030397A1Genetic material ingredientsNucleic acid vectorFarnesoid X receptorResponse element
Provided herein is a method for user controlled gene expression. In one embodiment, provided is a method for the activation of a T cell, comprising the steps of ectopically expressing farnesoid X receptor (FXR) in said T cell; activating said FXR; and transcribing a gene that contains a farnesoid response element (FRE) in a promoter region.
Owner:MUSC FOUNDATION FOR RESEARCH DEVELOPMENT(US)

Nucleic acids for inhibiting expression of MASP-2 in a cell

PendingUS20250230441A1Organic active ingredientsDNA/RNA fragmentationDiseaseEctopic expression
The invention relates to double-stranded nucleic acid molecules that interfere with or inhibit mannan-binding lectin serine protease 2 (MASP-2) gene expression. It further relates to therapeutic uses of such inhibition such as for the treatment of diseases and disorders associated with complement pathway deregulation, particularly of the Lectin pathway, and / or with over-activation or with ectopic expression or localisation or accumulation, of MASP-2 in the body.
Owner:SILENCE THERAPEUTICS GMBH